How to Test for Antiarrhythmic Drugs
I have been asked to consider several related questions. First: When during drug development and testing should electrophysiologic data be acquired? Second, what methods should be used to acquire this data? And, finally, during screening should one employ models of arrhythmias caused by ischemia or models of other sorts?
KeywordsAntiarrhythmic Drug Action Potential Duration Purkinje Fiber Cardiac Sodium Channel Fast Channel
Unable to display preview. Download preview PDF.
- 4.Bean BP, Cohen CJ, Tsien RW: Lidocaine binding to resting and inactivated cardiac sodium channels. Biophys J 33: 208, 1981.Google Scholar
- 11.Roden DM, Hoffman BF: Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circulation (in press).Google Scholar
- Sasyniuk BI, Ogilvie RI: Antiarrhythmic drugs: Electrophysiological and pharmacokinetic considerations. Ann Rev Pharmacol Toxicol 15: 131–155, 1975.Google Scholar